• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Christopher Marshall (doctor)     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatFellowsOfTheRoyalSociety, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingfoaf:Personpersondul:NaturalPersonEukaryotePersonHumanAnimalanimaleukaryotescientistspeciesschema:Personyago:WikicatLivingPeopleScientistyago:Associate109816771yago:CausalAgent100007347yago:Colleague109935990yago:LivingThing100004258yago:Object100002684yago:Organism100004475yago:Peer109626238yago:Person100007846yago:PhysicalEntity100001930yago:YagoLegalActoryago:YagoLegalActorGeoyago:Scientist110560637yago:Whole100003553yago:WikicatFellowsOfTheRoyalSociety New Facet based on Instances of this Class

Christopher John Marshall FRS FMedSci (19 January 1949 – 8 August 2015) was a British scientist who worked as director of the Division for Cancer Biology at the Institute of Cancer Research. Marshall was distinguished for research in the field of tumour cell signalling. His track record includes the discovery of the N-Ras oncogene, the identification of farnesylation of Ras proteins, and the discovery that Ras signals through the MAPK/ERK pathway. These findings have led to therapeutic development of inhibitors of Ras farnesylation, MEK and B-Raf.